Detalles de la búsqueda
1.
Long-term prognostic value of the GenesWell BCT score in Asian women with hormone receptor-positive/HER2-negative early breast cancer.
Breast Cancer;
31(1): 31-41, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37812303
2.
Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy.
Breast Cancer Res Treat;
199(2): 231-241, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-36947277
3.
Adjuvant trastuzumab without chemotherapy for treating early HER2-positive breast cancer in older patients: A propensity score-adjusted analysis of a prospective cohort study.
Breast;
66: 245-254, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36371994
4.
Pertuzumab retreatment for HER2-positive advanced breast cancer: A randomized, open-label phase III study (PRECIOUS).
Cancer Sci;
113(9): 3169-3179, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35754298
5.
Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial.
Lancet Oncol;
23(5): 636-649, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35405087
6.
A phase II study of sequential treatment with anthracycline and taxane followed by eribulin in patients with HER2-negative, locally advanced breast cancer (JBCRG-17).
Breast Cancer Res Treat;
190(3): 425-434, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34554370
7.
Health-Related Quality of Life With Trastuzumab Monotherapy Versus Trastuzumab Plus Standard Chemotherapy as Adjuvant Therapy in Older Patients With HER2-Positive Breast Cancer.
J Clin Oncol;
39(22): 2452-2462, 2021 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33835842
8.
Efficacy of the eribulin, pertuzumab, and trastuzumab combination therapy for human epidermal growth factor receptor 2-positive advanced or metastatic breast cancer: a multicenter, single arm, phase II study (JBCRG-M03 study).
Invest New Drugs;
39(1): 217-225, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32833136
9.
Prospective observational study of bevacizumab combined with paclitaxel as first- or second-line chemotherapy for locally advanced or metastatic breast cancer: the JBCRG-C05 (B-SHARE) study.
Breast Cancer;
28(1): 145-160, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-32715420
10.
Randomized Controlled Trial of Trastuzumab With or Without Chemotherapy for HER2-Positive Early Breast Cancer in Older Patients.
J Clin Oncol;
38(32): 3743-3752, 2020 11 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32936713
11.
Multicenter study of primary systemic therapy with docetaxel, cyclophosphamide and trastuzumab for HER2-positive operable breast cancer: the JBCRG-10 study.
Jpn J Clin Oncol;
50(1): 3-11, 2020 Jan 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-31821506
12.
Diffuse distribution of tumor-infiltrating lymphocytes is a marker for better prognosis and chemotherapeutic effect in triple-negative breast cancer.
Breast Cancer Res Treat;
178(2): 283-294, 2019 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-31402409
13.
Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study.
Breast Cancer Res Treat;
173(1): 123-133, 2019 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-30242578
14.
[A Phase I Combination Dose-Escalation Study of Eribulin Mesylate and Gemcitabine in Japanese Patients with Metastatic Breast Cancer].
Gan To Kagaku Ryoho;
45(8): 1165-1170, 2018 08.
Artículo
en Japonés
| MEDLINE | ID: mdl-30158412
15.
A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS study.
Jpn J Clin Oncol;
48(9): 855-859, 2018 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30020510
16.
Sporadic breast metastasis derived from renal cell carcinoma: A case report.
Urol Case Rep;
16: 126-128, 2018 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-29255682
17.
Objective evaluation of chemotherapy-induced peripheral neuropathy using quantitative pain measurement system (Pain Vision®), a pilot study.
J Pharm Health Care Sci;
3: 21, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28770097
18.
Randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.
Cancer Sci;
108(5): 987-994, 2017 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-28256066
19.
First-line bevacizumab plus paclitaxel in Japanese patients with HER2-negative metastatic breast cancer: subgroup results from the randomized Phase III MERiDiAN trial.
Jpn J Clin Oncol;
47(5): 385-392, 2017 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28158579
20.
The effectiveness of regional cooling for paclitaxel-induced peripheral neuropathy.
J Pharm Health Care Sci;
2: 33, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27891244